@prefix n9j: <http://data.loterre.fr/ark:/67375/N9J> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix isothes: <http://purl.org/iso25964/skos-thes#> .

n9j:-X53K2K0F-1
  skos:prefLabel "treatment theories, research, techniques, strategies, and effectiveness"@en ;
  a skos:Concept ;
  skos:narrower n9j:-D8NLZG02-H .

n9j: a skos:ConceptScheme .
n9j:-MB48CG9B-5
  skos:prefLabel "drug classification"@en ;
  a skos:Concept ;
  skos:narrower n9j:-D8NLZG02-H .

n9j:-D8NLZG02-H
  owl:sameAs <https://concepts.sagepub.com/social-science/concept/levo-alpha_acetyl_methadol> ;
  skos:definition "There are currently three Food and Drug Administration (FDA)-approved opioid agonist treatments for opioid addiction, which include methadone hydrochloride, buprenorphine hydrochloride, and levo-alpha acetyl methadol (LAAM). All three of these drugs are long-acting opioids, which bind to opioid receptors and thus block opioids from binding to these receptors. [Source: Encyclopedia of Substance Abuse Prevention, Treatment, & Recovery; Levo-Alpha Acetyl Methadol]"@en ;
  a skos:Concept ;
  skos:inScheme n9j: ;
  skos:broader n9j:-X53K2K0F-1, n9j:-MB48CG9B-5 ;
  skos:prefLabel "levo-alpha acetyl methadol"@en .

n9j:-concepts
  a isothes:ConceptGroup ;
  skos:prefLabel "concepts"@en ;
  skos:member n9j:-D8NLZG02-H .